TEL AVIV, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc. ("Clearmind") (NASDAQ:CMND) (CSE:CMND) (FSE: CWY), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental health problems, Clearmind filed three patent applications under the international Patent Cooperation Treaty ("PCT").
The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide ("PEA"), the active ingredient of SciSparc's proprietary CannAmide™. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office ("USPTO").
As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which ...